Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in

Alexander P Tuckow1, Sarah J Jefferson, Scot R Kimball

  • 1Dept. of Cellular & Molecular Physiology, The Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA.

Insights

Statins reduce muscle protein synthesis by decreasing eukaryotic initiation factor 2B (eIF2B) expression and activity. This effect, linked to statin-induced myotoxicity, was reversed by mevalonate.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Statins, widely used cholesterol-lowering drugs, are associated with muscle-related side effects (myotoxicity).
  • Mechanisms of statin-induced myotoxicity involve disruptions in muscle protein synthesis and degradation pathways.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying statin-induced reduction in protein synthesis in muscle cells.
  • To explore the role of eukaryotic initiation factor 2B (eIF2B) in simvastatin-induced myotoxicity.

Main Methods:

  • C₂C₁₂ muscle cells were treated with simvastatin (10 microM) or vehicle.
  • Protein synthesis rates were measured using [(35)S]methionine and [(35)S]cysteine incorporation.
  • Expression and activity of eIF2B, and phosphorylation of its ε-subunit, were assessed.
  • Proteasome sensitivity was evaluated.

Main Results:

  • Simvastatin treatment significantly reduced protein synthesis rates in C₂C₁₂ cells.
  • A decrease in both the expression and activity of eukaryotic initiation factor 2B (eIF2B) was observed.
  • Mevalonate co-incubation prevented the simvastatin-induced reductions in protein synthesis and eIF2B levels.
  • Simvastatin induced a proteasome-sensitive decrease in eIF2B protein expression and increased phosphorylation of the eIF2B ε-subunit.

Conclusions:

  • Repression of eIF2B expression and activity is a key mechanism contributing to statin-induced reduction in muscle protein synthesis.
  • These findings provide insights into the molecular basis of statin-induced myotoxicity.
  • Targeting eIF2B regulation may offer strategies to mitigate statin-associated muscle problems.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the addition of a...